Posted On: 12/22/2016 9:21:11 AM
Post# of 111
RDHL ..3 MEGA Drugs with Phase 3 Results in 1H 2017
RDHL is a brutally undervalued and almost unknown gem with many News coming within 6-7 months including Phase 3 Results from 2 Potential Blockbusters and NDA resubmission in early 2017 . Market Cap of around $150 Million and $60+ Million in cash makes this Biotech one of the most attractive in the Sector . This low float Stock is a gift below $10 with good News we could see $50 easily by end of next year .
Market Cap :$148 Million
Cash: $62 Million
Price: 9.70
Shares out 15 Million (50% of Shares held by Insiders alone)
New Presentation
http://files.shareholder.com/downloads/AMDA-1...51216_.pdf
Upcoming Milestones Q4 2016:
Commercial asset: •Potential acquisition of certain commercial rights to GI asset currently on the market in the U.S.
1H 2017 :
RIZAPORT®(RHB-103):
•Re-submission of U.S. NDA
RHB-104:
•Second DSMB meeting for the MAP US Phase III study for Crohn’s disease, including safety and interim efficacy analysis, with evaluation of option of early stop for success for overwhelming efficacy -Q2/2017 <<<<<<<< POTENTIAL BLOCKBUSTER ..GLOBAL MARKET SIZE : $5+ BILLION
BEKINDA®(RHB-102):
•Top-line Phase III results (gastroenteritis) -mid-2017 <<<< MARKET SIZE $650+ MILLION
•Top-line Phase II results (IBS-D) -mid-2017
RHB-105 (H. pylori):
First Phase III study successfully met its primary endpoint with high statistical significance (p<0.001), confirmatory Phase III planned to be initiated H1/2017 <<<< POTENTIAL BLOCKBUSTER ..GLOBAL MARKET SIZE : $4+ Billion
[IMG]http://wsw.com/webcast/jmp29/rdhl/3__SlideHMMJLF4.JPG[/IMG]
RDHL is a brutally undervalued and almost unknown gem with many News coming within 6-7 months including Phase 3 Results from 2 Potential Blockbusters and NDA resubmission in early 2017 . Market Cap of around $150 Million and $60+ Million in cash makes this Biotech one of the most attractive in the Sector . This low float Stock is a gift below $10 with good News we could see $50 easily by end of next year .
Market Cap :$148 Million
Cash: $62 Million
Price: 9.70
Shares out 15 Million (50% of Shares held by Insiders alone)
New Presentation
http://files.shareholder.com/downloads/AMDA-1...51216_.pdf
Upcoming Milestones Q4 2016:
Commercial asset: •Potential acquisition of certain commercial rights to GI asset currently on the market in the U.S.
1H 2017 :
RIZAPORT®(RHB-103):
•Re-submission of U.S. NDA
RHB-104:
•Second DSMB meeting for the MAP US Phase III study for Crohn’s disease, including safety and interim efficacy analysis, with evaluation of option of early stop for success for overwhelming efficacy -Q2/2017 <<<<<<<< POTENTIAL BLOCKBUSTER ..GLOBAL MARKET SIZE : $5+ BILLION
BEKINDA®(RHB-102):
•Top-line Phase III results (gastroenteritis) -mid-2017 <<<< MARKET SIZE $650+ MILLION
•Top-line Phase II results (IBS-D) -mid-2017
RHB-105 (H. pylori):
First Phase III study successfully met its primary endpoint with high statistical significance (p<0.001), confirmatory Phase III planned to be initiated H1/2017 <<<< POTENTIAL BLOCKBUSTER ..GLOBAL MARKET SIZE : $4+ Billion
[IMG]http://wsw.com/webcast/jmp29/rdhl/3__SlideHMMJLF4.JPG[/IMG]
(0)
(0)
